or
forgot password

    • cancer clinical trials in fresno, CA

    • Radiation Therapy With or Without SU5416 in Treating Patients With Soft Tissue Sarcoma
    Saint Agnes Cancer Center
    Fresno, California 93720
    Sarcoma
    Chemotherapy, SU5416, Radiation Therapy, and Surgery in Treating Patients With Soft Tissue Sarcoma
    California Cancer Center

    Trial Locations
    California Cancer Center
    Saint Agnes Cancer Center
    Sarcoma
    S0200 Carboplatin With or Without Doxil in Patients With Recurrent Ovarian Cancer
    California Cancer Center at Woodward Park Office
    Fresno, California 93720
    Ovarian Cancer, Peritoneal Cavity Cancer
    S0124: Cisplatin Combined With Either Irinotecan or Etoposide in Treating Patients With Extensive-Stage Small Cell Lung Cancer
    California Cancer Center - Woodward Park Office
    Fresno, California 93720
    Lung Cancer
    Proleukin in Combination With Rituxan in Patients With Low-Grade Non-Hodgkin's Lymphoma Who Have Previously Failed Rituxan Treatments
    California Oncology of the Central Valley
    Fresno, California 93710
    Lymphoma, Non-Hodgkin
    Radiation Therapy in Treating Patients With Metastases to the Lymph Nodes in the Neck From an Unknown Primary Tumor
    California Cancer Center

    Trial Locations
    California Cancer Center
    Saint Agnes Cancer Center
    Carcinoma of Unknown Primary
    Comparison of Nutritional Supplements in Preventing Weight Loss in Patients With Cancer
    California Cancer Center - Woodward Park Office
    Fresno, California 93720
    Cachexia, Lymphoma, Lymphoproliferative Disorder, Unspecified Adult Solid Tumor, Protocol Specific
    Irinotecan in Treating Patients With Refractory Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer
    California Cancer Center
    Fresno, California 93720
    Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
    S0216, Combination Chemotherapy and RT in Treating Patients With Stage III or Stage IV Head and Neck Cancer
    California Cancer Center
    Fresno, California 93720
    Head and Neck Cancer
    Study of Oxaliplatin/5-FU/Leucovorin Plus Vatalanib Versus Oxaliplatin/5-FU/Leucovorin in Patients With Previously Treated Metastatic Colorectal Cancer
    California Oncology of the Central Valley
    Fresno, California 93710
    Colorectal Neoplasms, Colonic Neoplasms, Rectal Neoplasms
    Study of Oxaliplatin/5-FU/Leucovorin Plus Vatalanib Versus Oxaliplatin/5-FU/Leucovorin in Patients With Metastatic Colorectal Cancer.
    California Oncology of the Central Valley
    Fresno, California 93710
    Colorectal Neoplasms, Colonic Neoplasms, Rectal Neoplasms
    Study of a 6-Month Sustained-Release Formulation of Leuprolide Acetate in Prostate Cancer
    Urology Associates Of Central California
    Fresno, California 93720
    Prostatic Neoplasms
    TLK286 (Telcyta) vs. Doxil/Caelyx or Hycamtin in Platinum Refractory or Resistant Ovarian Cancer
    California Oncology of the Central Valley
    Fresno, California 93710
    Ovarian Neoplasms
    Gemcitabine With or Without Radiation Therapy in Treating Patients With Pancreatic Cancer
    California Cancer Center - Woodward Park Office
    Fresno, California 93720
    Pancreatic Cancer
    Satraplatin in Hormone Refractory Prostate Cancer Patients Previously Treated With One Cytotoxic Chemotherapy Regimen
    California Cancer Center
    Fresno, California 93720
    Prostate Cancer, Hormone Refractory Prostate Cancer
    S0205 Gemcitabine w/ or w/o Cetuximab as First-Line Therapy in Locally Advanced Pancreas Cancer
    California Cancer Center - Woodward Park Office
    Fresno, California 93720
    Pancreatic Cancer
    Octreotide in Preventing or Reducing Diarrhea in Patients Receiving Chemoradiotherapy for Anal or Rectal Cancer
    California Cancer Center - Woodward Park Office

    Trial Locations
    California Cancer Center - Woodward Park Office
    Saint Agnes Medical Center
    Anal Cancer, Colorectal Cancer, Drug/Agent Toxicity by Tissue/Organ, Radiation Enteritis
    Melphalan, Arsenic Trioxide, and Ascorbic Acid in Treating Patients With Relapsed or Refractory Multiple Myeloma
    Hematology-Oncology Medical Group of Fresno, Incorporated
    Fresno, California 93720
    Stage II Multiple Myeloma, Stage III Multiple Myeloma, Refractory Plasma Cell Neoplasm
    XERECEPT® (hCRF) for Patients Requiring Dexamethasone to Treat Edema Associated With Brain Tumors
    UCSF Fresno Center for Clinical Studies
    Fresno, California 93702
    Brain Edema, Brain Tumor
    Onercept in the Treatment and Re-Treatment of Subjects With Moderate to Severe Plaque Psoriasis
    Associates in Research Inc.
    Fresno, California 93710
    Psoriatic Arthritis
    A Study to Evaluate Psoriasis Outcomes and Safety Events in Patients With Chronic Moderate to Severe Plaque Psoriasis (RESPONSE)
    Associates In Research, Inc.

    Trial Locations
    Associates In Research, Inc.
    Minarets Medical Group
    Psoriasis
    The Plenaxis® Experience Study
    Hematology-Oncology Group of Fresno
    Fresno, California 93720
    Prostate Cancer
    A Multiple Myeloma Trial in Patients With Bone Metastases
    California Oncology of the Central Valley
    Fresno, California 93710
    Multiple Myeloma
    Toremifene Citrate for Prevention of Bone Fractures in Men With Prostate Cancer on Androgen Deprivation Therapy
    Urological Associates of Central CA
    Fresno, California 93720
    Prostate Cancer, Osteoporosis, Fractures
    Cetuximab, Bevacizumab & 5FU/Leucovorin vs. Oxaliplatin, Bevacizumab & 5FU/Leucovorin in Metastatic Colorectal Cancer
    Cancer Care Associates of Fresno Medical Group, Inc (aka California Cancer Care)
    Fresno, California 93720
    Colorectal Cancer Metastatic
    Placebo Controlled, Randomized Safety and Efficacy Study of RC-1291 in Cancer Anorexia/Cachexia.
    Advanced Medical Research Institute
    Fresno, California 93710
    Cancer Cachexia
    A Survival Study for Women With Advanced Lung Cancer Who Have Not Previously Received Chemotherapy.
    Hematology/Oncology Group of Fresno, Inc
    Fresno, California 93720
    NSCLC
    Weekly vs. Every 2 Week vs. Every 3 Week Administration of ABI-007 (Abraxane)/Bevacizumab Combination in Metastatic Breast Cancer
    California Oncology of the Central Valley
    Fresno, California 93710
    Breast Neoplasms, Neoplasm Metastasis
    A Phase II Study of MDX-060 in Subjects With Relapsed or Refractory Hodgkin's Disease
    California Oncology of the Central Valley
    Fresno, California 93710
    Hodgkin's Disease
    MDX-060 in Patients With Relapsed or Refractory Classic Systemic or Primary Cutaneous Anaplastic Large Cell Lymphoma
    California Oncology of the Central Valley
    Fresno, California 93710
    Lymphoma, Large-Cell
    Combination Chemotherapy With or Without Bevacizumab in Treating Patients Who Have Had Surgery for Stage II or Stage III Rectal Cancer (Groups I and II Closed to Accrual as of 4/29/2009)
    Cancer Care Associates of Fresno Medical Group Inc
    Fresno, California 93720
    Adenocarcinoma of the Rectum, Stage II Rectal Cancer, Stage III Rectal Cancer
    Bortezomib, Ascorbic Acid, and Melphalan in Treating Patients With Newly Diagnosed Multiple Myeloma
    Hematology-Oncology Medical Group of Fresno, Incorporated
    Fresno, California 93720
    Multiple Myeloma and Plasma Cell Neoplasm
    A Study of ATN-224 and Bortezomib in Patients With Multiple Myeloma
    Hematolgy-Oncology Medical Group of Fresno, Inc.
    Fresno, California 93720
    Multiple Myeloma
    Safety and Efficacy Study of Glufosfamide in Patients With Recurrent Sensitive Small Cell Lung Carcinoma
    California Cancer Center
    Fresno, California 93720
    Carcinoma, Small Cell Lung
    Safety and Efficacy Study of Glufosfamide in Ovarian Cancer
    California Cancer Center
    Fresno, California 93720
    Ovarian Cancer
    Assessment and Tracking of Long-term Alefacept Safety
    Minarets Medical Group, Inc.
    Fresno, California 93711
    Psoriasis
    Safety and Efficacy Study of GCSF Therapy to Treat Patients at High Risk for Chemotherapy Induced Severe Neutropenia
    California Cancer Center
    Fresno, California 93720
    Breast Cancer, Neutropenia
    AMR PH GL 2007 CL001 Phase 3 Trial in Patients With Small Cell Lung Cancer After Failure of First-Line Chemotherapy
    Cancer Care Associates of Fresno Medical Group, Inc.
    Fresno, California 93720
    Small Cell Lung Cancer
    Bevacizumab and Sorafenib in Treating Patients With Recurrent Glioblastoma Multiforme
    Cancer Care Associates
    Fresno, California 93720
    Brain and Central Nervous System Tumors
    A Study of Leuprolide to Treat Prostate Cancer
    Site Reference ID/Investigator# 8686
    Fresno, California 93720
    Prostate Cancer
    Randomized Study to Compare CyberKnife to Surgical Resection In Stage I Non-small Cell Lung Cancer
    Community Regional Medical Center
    Fresno, California 93721
    Non-small Cell Lung Cancer
    A Study of Degarelix in Patients With Prostate Cancer
    Urology Associates Of Central California
    Fresno, California 93720
    Prostate Cancer
    A Trial of Degarelix in Patients With Prostate Cancer
    Urology Associates of Central CA
    Fresno, California 93720
    Prostate Cancer
    A Study of Pegylated Liposomal Doxorubicin (PLD), Bortezomib, Dexamethasone and Lenalidomide for Patients With Relapsed/Refractory Multiple Myeloma
    Hematology-Oncology Medical Group of Fresno, Inc.
    Fresno, California 93720
    Relapsed/Refractory Multiple Myeloma
    Imetelstat in Combination With Paclitaxel (With or Without Bevacizumab) in Patients With Locally Recurrent or Metastatic Breast Cancer
    Cancer Care Associates
    Fresno, California 93720
    Locally Recurrent or Metastatic Breast Cancer